{"data":{"id":"us/21-cfr-316.4","jurisdiction":"us","citation":"21 CFR 316.4","heading":"Address for submissions.","body":"All correspondence and requests for FDA action under the provisions of this rule should be addressed as follows: Office of Orphan Products Development, Food and Drug Administration, Bldg. 32, Rm. 5271, 10903 New Hampshire Ave., Silver Spring, MD 20993.","path":["Title 21—Food and Drugs","CHAPTER I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES","SUBCHAPTER D—DRUGS FOR HUMAN USE","PART 316—ORPHAN DRUGS","Subpart A—General Provisions"],"source_url":"https://www.ecfr.gov/api/versioner/v1/full/2026-08-25/title-21.xml","current_through":"2026-08-25","vintage":"","retrieved_at":"2026-08-27T02:24:47Z","sha256":"23c10589145b612e557eb434fc752e125cfd98c0fe03ca163b0941add83fd7f5","source_id":"us-cfr","stale":true,"prev":"us/21-cfr-316.3","next":"us/21-cfr-316.10"},"notice":"GroundRules: Original legal text. Not legal advice."}